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Clq is a 410,000 mol wt glycoprotein that circulates in plasma at a concentra- 
tion of 65-70 #g/ml and constitutes a subunit of the first component of comple- 
ment, C 1 (1). In plasma, C 1 circulates as a calcium ion-dependent pentamolecular 
complex  consisting  of one  molecule  of C lq,  two  molecules of Clr,  and  two 
molecules of Cls, to give a  structural  formula,  ClqlClr~Cls2  (2). During acti- 
vation of the classical pathway of complement, Clq,  within the C1  macromole- 
cule, functions as the recognition unit (3) by virtue of its ability to recognize and 
bind to the Cn2 domain of IgG (4, 5) and Cn3 or Cn4 domains of IgM (6, 7). It 
is a collagen-like molecule (1) with six flower-like globular heads that constitute 
the binding  sites for Ig (4).  Each globular head contains the carboxyl-terminal 
ends  of three  similar  but  distinct  polypeptide  chains  (A,  B,  C)  of ~20,000- 
22,000 tool wt that occur six times in the molecule, forming six structural and 
functional  subunits  (3,  8,  9).  The  amino-terminal  regions  of each  chain  are 
collagen-like and  associate  to  form a  helical  configuration  that  represents  the 
binding sites for C 1  r~C 1  s~ (9-10). 
In addition to being a recognition unit of the classical pathway of complement, 
C l q functions as a  ligand for a  number of cellular receptors (recently reviewed 
in. 11) such as B lymphocytes (12,  13), lymphoblastoid cells (14,  15), null cells, 
monocytes, polymorphonuclear leukocytes (16, 17), fibroblasts (18), and platelets 
(19, 20); and the binding of C lq to certain  types of cells elicits some biological 
functions.  For  instance,  we  have  shown  previously  (15)  that  lymphocytes  or 
lymphoblastoid cells such as Raji cells are  capable of lysing Clq-coated,  chro- 
mium-labeled chicken erythrocyte (Ec) l target cells. That the pre-killing, effector 
cell-target cell contact is mediated by the effector celt C 1  q receptor (C 1  qR) was 
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demonstrated by pretreatment of the target cells with F(ab')~ anti-Clq, which 
abrogated the cytotoxic effect (15).  Furthermore, monomeric C 1  q was reported 
to inhibit the collagen-dependent aggregation of platelets (19, 20) and the release 
of serotonin (21).  The importance of C lqR  was not fully appreciated,  partly 
because,  in  normal serum,  Clq  occurs as a  subunit of the  C1  complex.  The 
amount of available free C 1  q was therefore thought to be very small. However, 
ClqR  assumed  new  significance  after  it  was  observed  that  CT-INA,  the 
plasma inhibitor of activated C 1, rapidly dissociates the activated C 1  r  and C 1  s 
subunits from the C1  complex (22),  thus leaving Clq bound to immune com- 
plexes. 
In previous reports (23, 24), it was shown that a substance could be solubilized 
from membranes of lymphocytes or iymphoblastoid cells (Raji) that possesses the 
property of binding and precipitating free C 1  q, and hence was described as a 
C 1  q precipitin (23) or membrane-derived C 1  q  inhibitor (M-C 1  qINH  s) (24).  In 
the  present  study, evidence  is  presented  demonstrating that  this  membrane- 
derived inhibitor constitutes the cellular receptor for C 1  q. 
Materials and Methods 
Materials.  The following materials were purchased:  Nonidet P-40 (NP-40), lactoper- 
oxidase, glutaraldehyde (Sigma Chemical Co., St. Louis, MO); Na~SI and Bolton-Hunter 
reagent (New England Nuclear, Boston, MA); Ficoll-Hypaque (Pharmacia Fine Chemical, 
Piscataway, NJ), cyanogen bromide (CNBr) (Eastman Kodak Co., Rochester,  NY), N,N- 
dimethyiformamide (Aldrich Chemical Co., Milwaukee, WI), polyethylene glycol (PEG) 
(PEG 6000;  Fisher Scientific Co.,  Pittsburgh,  PA), and RPMI and other tissue culture 
reagents (Gibco Laboratories, Grand Island, NY). 
Purified Proteins.  Highly purified Clq.was isolated according to a method previously 
described (25) and the protein concentration determined either by the method of Lowry 
et al. (26) or by measuring the optical density at 280 nM and using an extinction coefficient 
E~cm of 6.8. The homogeneity  of a representative preparation  of C 1  q used in these studies 
is shown in Fig. I. 
Radioiodination  of Proteins.  All radiolabeled  proteins  were  labeled  with  lesI by the 
Boiton-Hunter method as described (27) unless otherwise specified. Typically, 100 ~g of 
isolated protein in 0.1 M sodium borate buffer (pH 8.5) were added to 100/~Ci of Bolton- 
FIGURE  1.  SDS-PAGE  (7%) analysis  of highly  purified human Clq. Each gel contained 20 
t~g of protein. Unreduced  human Clq consists  of six A-B dimers and three C-C dimers that 
upon reduction yield  equimolar amounts  of three chains designated  A, B, and C. GHEBREHIWET, SILVESTRI, AND  McDEVITT  1377 
Hunter reagent and allowed to react for 30 min at 4°C. The reaction mixture was then 
dialyzed against phosphate-buffered saline (PBS),  pH 7.0, at 4°C until the dialysate was 
free of 12SI. 
Preparation of Clq-Sepharose 4B.  Highly purified Clq  was coupled to Sepharose 4B 
according to the method described by March et al. (28). Briefly, 50 mi of packed Sepharose 
4B was washed extensively with  deionized  water and  resuspended  in  50  ml of 5  mM 
potassium phosphate tribasic buffer, pH  12.5 and stirred in an ice bath kept in a  fume 
hood for 15 min. Then 7 g of CNBr dissolved in 3.5 ml of N,N-dimethylformamide were 
quickly added and the mixture was stirred for 5  rain. The Sepharose beads were then 
washed in a  Buchner filter funnel in the fume hood with 2 liters of water followed by 2 
liters of coupling buffer consisting of 8 g  NaHCOs, 29.2 g  NaCI/1, pH 9.0.  The CNBr- 
activated Sepbarose was mixed  in  a  wide-mouth,  250-ml  plastic bottle  with  50  ml  of 
human Clq (2 mg/ml) that had been dialyzed against coupling buffer, and the mixture 
was left for 16 h at 4°C with continuous stirring, after which it was placed in a Buchner 
funnel and evacuated to dryness. The amount of protein coupled to the Sepharose was 
determined by assaying the protein content in the filtrate. The Clq-Sepharose was then 
washed with 1 liter of PBS, pH 7.0 and resuspended in 50 ml of 1 M glycine, pH 8.0 for 
2 h at 22°C to block the unreacted sites on the Sepharose beads. The slurry was washed 
by filtration with  1 liter of 5 mM sodium phosphate buffer, pH 7.5, containing 0.5 mM 
EDTA, 150 mM NaC1, and 0.02% NaNs, and poured into a  1.5 x  20 cm column. Before 
each use, the Clq-Sepharose column was tested for its activity by taking 0.5 ml of packed 
beads and incubating them with 0.2 m] of monospecific, polyclonal antiserum to Clq for 
1 h  at  4°C.  After incubation  the  mixture was centrifuged  (500  rpm,  5  min) and  the 
remaining anti-Clq activity of the supernatant tested by Ouchterlony analysis, as shown 
in Fig. 2. 
Lymphoblastoid Cell Line.  The  cell  line,  Rail,  used  in  this  study  was  taken  from a 
continuous culture  line propagated in  RPMI  containing  10%  fetal calf serum and  1% 
antibiotic-antimycotic mixture and was originally derived from a  patient with Burkitt's 
lymphoma (29, 30). 
Purification of Clq Receptor.  The purification of ClqR was essentially the same as that 
described  earlier (24)  with  only minor modifications.  Briefly,  3  x  109  Raji  cells  were 
washed three times and resuspended in  100 ml of 5  mM sodium phosphate buffer, pH 
7.5, containing 0.5 mM EDTA, 150 mM NaCl, 10 mM EACA, and 0.5 mM phenylmeth- 
ylsulfonyl fluoride (PMSF). Cell membranes were prepared by freeze-thawing (five times) 
at -80°C and centrifugation for 1 h at 30,000 g at 4°C. The pelleted membranes were 
then solubilized by suspension in  50 m] of the above buffer containing  1%  NP-40 and 
stirred for 20 h  at 4°C. The solubilized membrane proteins were freed from insoluble 
material by centrifugation at 30,000 g for 60 min at 0°C and the total protein concentra- 
tion  was determined to be 30  mg. After dialysis against 5  mM  NaPO4 buffer, pH  7.5, 
containing 0.5 mM EDTA, 20 mM NaCI, 10 mM EACA, 0.5 mM PMSF, and 0.1% NP- 
40,  10  mg  of the  dissolved  membrane  solution  was applied  to  a  1.5  x  20  cm  Clq- 
Sepharose 4B column that had been equilibrated with the same buffer. The column was 
then washed with 600 ml of the starting buffer and the specifically bound proteins eluted 
with a  linear NaCI concentration gradient with 300 ml of starting buffer and 300 ml of 
same buffer containing  1 M NaCI. Fractions containing Clq-binding activity were deter- 
FIGURE 2.  Depletion of anti-Clq activity on a Clq-Sepharose 4B column. A sample of a 
monospecific, polyvalent antibody to C I q was incubated with C 1  q-coated Sepharose. Depletion 
of anti-C I q was another means of showing that the Sepharose beads were coated with the C 1  q 
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mined  by  single  or  double  immunodiffusion  techniques  in  a  0.8%  agarose  (sodium 
phosphate buffer, pH 7.2) containing 1.5% PEG 6000, using highly purified human Clq 
as described earlier (24,  31), and concentrated on an Amicon pressure filtration device 
with a  Diaflow UM-10  ultrafiltration  membrane (Amicon Corp.,  Danvers, MA). When 
the ClqR was used in a hemolytic assay, the detergent concentration was always reduced 
to ~0.01% by passage through a column of QAE-50 Sephadex as described (24). 
Sodium  Dodecyl Sulfate-Polyacrylamide Gel  Electrophoresis (SDS-PAGE) Analysis of 
ClqR.  After  radiolabeling  with  Bolton-Hunter  reagent  (27),  the  isolated  ClqR  was 
reduced and aikylated by boiling for 5 min in the presence of 0.1  M dithiothreitol (DTT) 
and 0.2  M  iodoacetamide and was analyzed by application on a  1.5-mm thick,  5-10% 
acrylamide  gradient  containing  slab  gels,  using  the  method  of  Laemmli  (32).  After 
electrophoresis, the gel was stained with Coomassie Blue, vacuum-dried, and analyzed by 
autoradiography. 
Ultracentrifugation Analyses.  Ultracentrifugation analysis of isolated ClqR was deter- 
mined on a 5-40% sucrose-containing linear gradient in 5 mM NaPO4 buffer containing 
90 mM NaCI, 10 mM EACA, 0.5 mM EDTA, 0.5 mM PMSF, and 0.1% NP-40, pH 7.4. 
Centrifugation was carried out in a  Beckman model L5-75B ultracentrifuge (Beckman 
Instruments,  Inc.,  Fullerton,  CA) using an  SW65  rotor for 20  h  at  50,000  rpm.  Clq 
(1 IS), C3 (9.5S), albumin (4.6S), and cytochrome c (1.7S) were used as markers. 
In another set of experiments, an equilibrium density gradient uitracentrifugation was 
run  in  the  following manner.  First,  the  isolated ClqR  was dialyzed overnight at 4°C 
against distilled water and then lyophilized. The dried residue was then dissolved in 8 ml 
of a solution comprised of 4 M guanidinium chloride, 0.05 M sodium acetate, pH 5.8, N- 
ethyl malimide, 0.1  M EDTA, 0.1  M EACA, and 0.005  M benzamidine, that contained 
cesium chloride to a density of 1.5 g/ml. The solution was centrifuged at 12°C for 72 h 
at 100,000 rpm in a Beckman ultracentrifuge using a swing-out rotor (SW60). The tubes 
were then frozen in liquid nitrogen and cut into two fractions: the bottom 2/5 and the 
bottom 3/5 by volume. The fractions were then dialyzed against 0.2  M sodium acetate, 
pH 5.8 and then against distilled water at 4°C.  Finally, the material was lyophilized and 
then dissolved in  1.0 ml of distilled water. Protein and uronate were determined on an 
autoanalyzer (Techicon Instruments Corp., Tarrytown, NY). 
Amino Acid Analysis.  Amino acid analysis was performed with an amino acid analyzer 
(model 121M; Beckman Instruments, Spinco Division, Palo Alto, CA) equipped with an 
automatic sample injector  and a  model  System AA automatic digital  integrator.  The 
sample was hydrolyzed in  6  N  HCI for 20 h  at  110°C  in evacuated and sealed Pyrex 
tubes. ~25 nmol of hydrolyzed protein were applied to each column and the amino acid 
concentration  was determined by comparison with a  standard  mixture of amino acids 
(100 nmoi/ml). 
Effect ofChondroitinase ABC on ClqR.  To determine the effect ofchondroitinase ABC, 
0.1 #g purified 125I-C  1  qR was dissolved in 0.1  ~i of Tris-HCi, pH 8.0, and incubated with 
buffer alone or with 0.1  U of enzyme as described previously (31) for 12 h at 37 °C. Then 
the sample was dialyzed against buffer containing 0.14  M  Na2SO4,  0.01  cacodylic acid, 
and  0.1%  NP-40.  The  chondroitinase-digested  sample  and  the  control  sample  were 
sequentially applied to a  column of Sepharose CL-6B (0.5  ×  120  cm; matrix,  108  cm) 
equilibrated with same buffer together with 250 ~g of bovine nasal cartilage proteoglycan 
AIDI (Vo marker, =2.2 ×  106 mol wt) and 20 #g glucuronolactone (Vt marker, =176 mol 
wt) and eluted with the same buffer at a flow rate of 5 ml[h. Fractions were analyzed by 
Ouchterlony using isolated C 1  q and by the carbazole method of uronic acid determination 
(33). 
Inhibition of EClq Rosettes by ClqR or Monoclonal Antibody to ClqR.  The ability of 
ClqR  to inhibit  Clq-dependent  rosette formation was determined  by a  previously de- 
scribed rosette assay (34, 35) and consists of the following steps. First, human erythrocytes 
(Eh) were treated with 100 voi of 2% glutaraldehyde in 0.15 M PBS, pH 7.4, at 4°C for 
16  h.  The  cells  were  washed  with  Hanks' balanced  salt solution  (HBSS) and  further 
incubated with  10 vol of HBSS containing  10 mg/ml L-lysine for 30 min at 37°C, after 
which the cells were washed and resuspended in HBSS at 1 ×  109/ml. Then 5 ×  108 cells GHEBREHIWET,  SILVESTRI,  AND  McDEVITT  1379 
in 1 ml HBSS were incubated with 200 t~g Clq and a tracer amount (1/~g) of t2sI-Clq (8 
× 105 cpm/ug). The excess unbound C 1  q was removed by centrifugation in HBSS. Rosette 
formation was then assayed by incubating 1.5 ×  107 Eh Clq with 5 ×  l0  s Raji cells in a 
total volume of 0.4 ml HBSS for 5 min at 37°C, centrifuging for 5 min at 600 rpm, and 
further incubation for 60  min at 4°C.  To determine the inhibitory effect of isolated 
ClqR, the Raji cells were either pretreated with 5 t~g/mi F(ab')~ or the reaction mixture 
was incubated in the presence of 5 gg C I qR. The percent rosettes formed was determined 
by counting at  least  100  lymphocytes in  a  microscope  (Microstar;  American  Optical 
Scientific Instruments, Buffalo, NY). 
Clq-dependent CytotoxicityAssay.  51Chromium-labeled,  Clq-coated chicken erythrocyte 
target cells (5~Cr-F~) were prepared  as described earlier (15).  The inhibitory effect of 
ClqR was tested by preincubating 10 ug ClqR with 8  ×  104 5~Cr-~  and leaving the 
excess unbound ClqR in the reaction mixture, which contained, in addition, 2 ×  10~Raji 
cells in a total volume of 0.4 ml of RPMI containing 0.4 human serum albumin, 2 mM L- 
glutamine, and 1% antibiotic-antimycotic mixture (penicillin  10,000 U/ml, fungizone 25 
t~g/ml,  streptomycin  10,000 mcg/ml).  Incubation was  carried  out at  37°C  in  a  CO2 
incubator for 20 h. After incubation, the reaction mixture was centrifuged for 10 rain at 
1,000 rpm, the radioactivity of both pellet and supernatant determined, and cell damage 
expressed as  the percentage of the  total radioactivity released  from the cell  into the 
supernatant. 
Effect of lsolated ClqR on Clq Hemolytic Function.  There is evidence in the literature 
indicating that the Clq receptor reacts with the collagen-like region of the molecule (16, 
24). Since this region also constitutes the site to which Clr and Cls bind, an experiment 
was performed to see if the isolated molecule could inhibit the hemolytic activity of C1 in 
serum. This was determined by incubating 5 #g/ml of purified ClqR (which had been 
repurified on a  QAE-Sephadex column to reduce the detergent concentration) with or 
without 50 ng of Clq for 60 min at 37°C, followed by an additional 60 min incubation 
in the presence of 10 ul of C1 q-depleted serum (containing 20 mM CaCI~) and antibody- 
sensitized sheep erythrocytes (EA) (5 ×  10S/ml) in a total volume of 0.5 ml GVB (veronal- 
buffered saline containing 0.15 mM CaCl~, 0.5 mM MgCI2, and 0.1% gelatin) (24). After 
incubation, the cells were centrifuged and the amount of hemoglobin released into the 
supernatants was determined spectrophotometrically at 700 nm. The inhibitory effect of 
the isolated substance was expressed as the percent inhibition of C 1  q hemolytic activity. 
Results 
Purification  of CIqR by Affinity Chromatography.  When  a  total of 10  mg of 
unlabeled  and  tracer  amount  (1  X  108  cpm/#g)  of surface-labeled,  NP-40- 
solubilized Raji cell membranes were chromatographed on a Clq-Sepharose 4B 
column and bound proteins eluted with a  linear NaCI concentration gradient, 
two discrete, Clq-reactive peaks eluted at approximately 22 and 30 mmho/cm, 
respectively (Fig. 3). This seems to suggest that Raji cells possess two species of 
receptors with different affinities or charge heterogeneity. The two peaks were 
then separately pooled, concentrated, and designated arbitrarily as C 1  q receptor 
I  and  I!  (ClqRI  and  -II).  From  the  tracer  amount  of radiolabeled  protein 
incorporated,  it was  determined that  the two  C lq-reactive  proteins  represent 
-7% of the total labeled Raji cell membrane proteins. 
Immunodiffusion Analysis oflsolated CIqR.  Equal concentrations of the pooled 
and concentrated peaks, C1 qRI and C l qRII, were tested for their ability to bind 
and precipitate Clq using double (Fig. 4A) and single (Fig. 4B) immunodiffusion 
techniques. Both pools were found to be reactive, although the precipitation ring 
obtained by  ClqRII  (Fig.  4B)  was apparently  stronger  than  that  for  ClqRI, 
probably  due  to  the  disparity  in  concentration,  since  ClqRII  was  found  to 1380 
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FIGURE 3.  Affinity chromatography of solubilized Raji cell proteins on a C 1  q Sepharose 4B 
column.  Pools I and  lI represent two peaks with Clq-binding activity. After concentration 
and repurification on  QAE-Sephadex, the pools were arbitrarily designated as CIqRI  and 
ClqRII. 
contain at  least two other protein bands (see below).  Furthermore, ClqR  was 
found to react with normal human serum (NHS) that contains EDTA but not 
NHS alone, indicating that under physiologic conditions where C 1  q is in complex 
with Clr2 and Cls2, the receptor does not bind to Clq in NHS. 
SDS-PAGE Analysis of ClqR.  Both ClqRI and ClqRII were radiolabeled with 
~sI and analyzed on a 10% SDS gels. As shown in Fig. 5, both ClqR preparations 
contained a major band (80-90 kD) that, under reducing conditions, resulted in 
a single, 60-70 kD band. However, while ClqRII was relatively homogeneous, 
ClqRI  was found to contain at least two distinctly visible bands that together 
represented ~50% of the preparation. 
It is also of interest that the ClqR molecule has a much more pronounced 1251 
band upon reduction than without reduction, indicating that the protein moiety 
might exist as a polymeric structure of disulfide-bonded 70,000  mol wt chains. 
Furthermore, some visible bands were observed at the top of the gel, and two or 
three protein bands were visible that did not label with ~5I. 
Ultracentrifugation  Analysis.  Sucrose density ultracentrifugation analysis re- 
vealed that the ClqR sediments at -4.2 S; the results of one such experiment is 
shown in  Fig.  6.  In addition,  equilibrium density gradient uhracentrifugation 
showed that the isolated receptor could be separated into a  protein-rich, low 
density fraction and a  carbohydrate-rich, high density fraction (Table I).  The 
large hydrodynamic size, coupled with the high buoyant density and uronic acid 
content, suggests that a proteoglycan is a constituent of the complex. 
Amino Acid Analysis.  The results of amino acid analysis data are represented 
in  Table  II.  One of the striking features is that ClqR  is rich in glycine, with 
glutamic acid and aspartic acid following closely behind, which explains its acidic GHEBREHIWET, SILVESTRI, AND  McDEVITT  1381 
FIGURE 4.  Immunodiffusion  analyses  of CIqR. Isolated receptor pools were analyzed  by 
double (A) and single (B) immunodiffusion  techniques. Both plates contained  0.8% agarose  in 
PBS, pH 7.4, 1.5% PEG, and 0.02% NaNs. The agarose in plate B contained,  in addition, 25 
~ag/ml of purified Clq. CIqRII precipitated Clq in NHS containing  EDTA (NHS-E) but not 
in NHS. 
nature. The hexosamine ratio, or the ratio of galactosamine to glucosamine, was 
found  to  be  3.2.  Furthermore,  the  uronic  acid  content  of a  typical  ClqR 
preparation was found to be 23%, while galactosamine content was 21%. 
Digestion of ClqR with  Chondroitinase  ABC.  Previous studies postulated that 
the plasma-derived C 1  q inhibitor, which was identified as a chondroitin 4-sulfate 
proteoglycan (31), and the lymphocyte  membrane-derived C lq inhibitor (C lqR), 
could be similar or identical. To assess this issue, an experiment was designed in 
which the ClqR  was incubated with either buffer or chondroitinase ABC,  as 
described in Materials and Methods. Both materials were then applied to a CL- 
6B column (0.5 x  120 cm; matrix height,  105 cm). After elution, it was found 
that the treated and untreated C l qR chromatographed in the same region, with 
a Kay of 0.45 (Fig. 7), indicating that ClqR is not digestable with chondroitinase. 
Furthermore, chondroitinase-digested C 1  qR did not lose its ability to precipitate 
Clq as assessed by a double radial immunodiffusion  analysis, as described. 
Inhibition of C l q-dependent Biological Functions by C I qR.  The ability of isolated 
ClqR to inhibit Clq-dependent rosette formation was tested by preincubating 
glutaraldehyde-treated, Clq-coated Eh with or without 5 #g/ml of the receptor 
and then with either peripheral blood lymphocytes that had been purified by 
centrifugation on Ficoll-Hypaque (36) or Raji cells for 60 min at 4°C. As shown 
in Table III, 5 #g/ml of ClqR was able to inhibit rosette formation. Furthermore, 1382  HUMAN  CELLULAR  Clq  RECEPTOR 
FIGURE  5.  SDS-PAGE  gel analysis of Clq-Sepharose pools. The pooled fractions in Fig. 3 
were concentrated and radiolabeled before further purification. The specific  activity was 7.7 
x  10  s and 5.1 x  10  s cpm/#g for pool I (ClqRI) and pool II (ClqRII), respectively. ~5 X 104 
cpm (~7 #g) of each sample was applied to a Laemmli slab gel (10%) in the absence (I and 3) 
or presence (2 and 4) of 0.1 M DTT. After electrophoresis the gel was stained with Coomassie 
Blue, vacuum-dried, and exposed in a Dupont Cronex cassette with Lightning Plus screens for 
24 h at -80°C before autoradiographic analysis. 
both the C 1  q-dependent cellular cytotoxicity (Table IV) and hemolytic functions 
(Table V) were found to be inhibited by ClqR. 
Discussion 
In  previous reports (23,  24) we isolated a  lymphocyte membrane-associated 
C 1  q precipitin (23) or M-C 1  q inhibitor (24) and demonstrated that it was capable 
of inhibiting some of the C 1  q-dependent biological functions. The questions that 
arose  from  these  studies  were:  (a)  What  is  the  exact  chemical  nature  of the 
membrane-derived Clq inhibitor? (b) What is its relationship to the plasma Clq 
inhibitor? and (c) Is the Clq inhibitor identical to the Clq receptor on lympho- 
cytes? To answer these questions and further characterize the chemical, as well 
as  the  functional  nature,  the  membrane-associated  inhibitor  was  isolated  to 
homogeneity  using  a  Clq-Sepharose  4B  affinity column  as  described  earlier 
(23).  The  present  results  clearly  demonstrate  that  the  isolated  Clq  inhibitor 
constitutes  the  cellular receptor for C l q  and  that  it  may  exist as  two  distinct 
populations  of receptors  possessing  different  affinities  for  the  C lq  molecule. GHEBREHIWET,  SILVESTRI,  AND  McDEVITT 
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FIGURE 6.  Sucrose density ultracentrifugation. Analysis of isolated C I qRII was determined 
in 5 mM NaPO, buffer containing 50 mM NaCI,  10 mM EACA, 0.5 mM EDTA, 0.5 mM 
PMSF, and 0.1% NP-40, pH 7.4. Centrifugation at 50,000 rpm was for 20 h at 4°C. 
TABLE  I 
Distribution of lsolated ClqR in Cesium Chloride Density Gradient 
Ultracentrifugation 
Fractions*  Density  Protein  Uronic acid 
g/ml  #g  #g 
Bottom  1.55  24  6.25 
Top  1.45  100  3.50 
* A  lyophylized preparation of CIqR  that  had been  dissolved in  4  M 
guanidinum chloride, containing 0.05  M sodium acetate, pH 5.8, N- 
acetyl maleimide, 0.1  M EDTA, 0.1  M amino-caproic acid, 0.005  M 
benzamidine, and  1.5 g/ml cesium chloride, was centrifuged at  12°C 
for 72 h. The fractions were collected by freezing the tubes and cutting. 
Protein and uronate were determined on a Technicon autoanalyzer. 
This  conclusion  is  derived  from  the  observations  that  when  the  detergent- 
solubilized membrane  proteins were applied to the C 1 q-Sepharose  4B column, 
washed  exhaustively,  and  the  adsorbed  materials  eluted,  two  discrete  peaks 
eluting  at  different  ionic  strengths  (22  and  30  mmho/cm,  respectively) were 
obtained. Both species had similar properties since both were capable of binding 1384  HUMAN  CELLULAR  Clq  RECEPTOR 
TABLE  II 
Amino Acid Composition of ClqR 
Total  Total 
Amino acid  nanomoles  Res/1,000  micrograms 
Aspartic acid  9.1  93.8  1.2 
Threonine  4.9  50.5  0.6 
Serine  8.0  82.5  0.8 
Glutamic acid  10.0  103.1  1.5 
Proline  7.9  81.4  0.9 
Glycine  18.5  190.7  1.4 
Alanine  7.3  75.3  0,6 
Cysteine  0.0  0.0  0.0 
Valine  4.1  42.3  0.5 
Methionine  0.0  0.0  0.0 
Isoleucine  2.5  25.8  0.3 
Leucine  7.6  78.4  1.0 
Tyrosine  3.0  30.9  0.5 
Phenylalanine  3.4  35.1  0.6 
Histidine  1.6  16.5  0.2 
Lysine  5.3  54.6  0.8 
Arginine  3.8  39.2  0.7 
Glucosamine  2.3  23.7  0.4 
Galactosamine  7.3  75.3  1.3 
The  percent  total  sample  on  the  column  is  67.28;  total  nanomoles  of 
amino acids,  97;  total  micrograms of protein,  11.6.  Hexosamine ratio: 
glucosamine/galactosamine, 0.3; galactosamine]glucosamine, 3.2. 
and precipitating free C 1  q, although the concentration of C 1  qRI (after further 
purification) required to precipitate the same amount of C l q was one-half that 
of pool II.  However, the conclusion that two distinct cell receptor populations 
might exist should await binding studies to determine their affinity constants. 
C 1  q possesses two binding sites for certain types of mucopolysaccharides such as 
low molecular weight heparin (37); the high affinity-binding site was shown to 
be the collagenous region of the molecule. That the Clq inhibitor is a  cellular 
receptor for Clq (ClqR) is inferred from the following lines of evidences. (a) 
When the isolated material or C 1  qR was preincubated with C 1  q-bearing, glutar- 
aldehyde-treated Eh, no rosette formation was obtained upon subsequent incu- 
bation  with  lymphocytes or  Raji  cells.  (b)  Clq-coated,  51Cr-labeled  chicken 
erythrocyte target cells were prevented from lysis by Raji cells when the target 
cells were first preincubated with the C lqR.  That this  complement-mediated 
cellular cytotoxicity (CDCC) is mediated by the effector celI-C l q  receptor has 
been previously documented (15).  (c) ClqR binds to free Clq and this ClqR- 
bound C 1  q was unable to reassemble and form a hemolytically active C 1 in the 
presence  of Clq-depleted  serum  and  20  mM  Ca  ++.  (d)  In  addition,  other 
experiments have shown that binding of 125I-Clq  to Raji cells was abrogated in 
the presence of C1 qR, indicating that the isolated receptor could compete for 28 
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FIGURE 7.  Chromatography of ClqR on Sepharose CL-6B. Radiolabeled  CIqRII was first 
incubated with buffer or digested  with  chondroitinase ABC, as described in Materials  and 
Methods, and then chromatographed in Sepharose  CL-6B (0.5 X 120 cm). 
TABLE  III 
Inhibition of Clq Rosettes by ClqR 
Reaction  mixtures  Percent rosettes* 
Raji + EClq  81 
Raft + (EClq + ClqR)*  7 
PBL + EClq  39 
PBL + (EClq + ClqR)  10 
* Rosettes  were formed by incubating 0.2 ml peripheral blood lympho- 
cytes (PBL) or Raji cells (2.5 X 108/ml) with 1.5 X l0  T Clq-coated (15 
#g) glutaraldehyde-treated human erythrocytes (EC I q) in a total volume 
of 0.4 ml HBSS for 5 min at 37°C, centrifuging 5 min at 600 rpm, and 
further incubating for 60 min at 4°C. 
* Inhibition of EC I q rosettes  by C l qR was determined by preincubating 
EClq with 5 #g/ml CIqR for 15 min at 37°C before incubation with 
lymphocytes or lymphoblastoid  cells. 
the  binding  of Clq.  (e)  Furthermore,  murine  F(ab')2  monoclonal  antibody  to 
ClqR  was found to inhibit  12~I-Clq binding to Raji cells. ~ 
The  Clq  molecule is collagen-like with six globular heads that are the binding 
sites  for Ig.  The  collageneous  tail  of the  molecule  is  considered  to be  the  site 
where  Clr  and  Cls  bind  in  plasma.  The  collageneous  region  of the  molecule 
constitutes  the site  through  which C l q  binds to receptors  (14-17).  Our  finding 
that  ClqR  was  unable  to  precipitate  Clq  in  serum  seems  to  confirm  these 
findings. 
The  results  obtained  from  equilibrium  gradient  ultracentrifugation  indicate 
2 Ghebrehiwet,  B. Murine monoclonal antibody that interacts  with human Clq receptor. Manu- 
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TABLE IV 
Inhibition  of C l q-dependent  Cytotoxicity by C I qR 
Percent 51Cr 
Reaction mixture  release* 
Raji + 51Cr-Ec  5 
Raji + 51Cr-Ec  Clq  74 
Raji + (ClqR + StCr-Ec  Clq)  10 
* 1 x  l0  s, 5*Cr-labeled,  Clq-coated E, target cells were incubated with 5 
x  105 Raji cells in the presence or absence of 5 t~g/ml ClqR in a total 
volume of 0.3 ml RPMI plus 5% FCS for 20 h at 37°C in an atmosphere 
of 95% air and 5% CO2. After incubation, cells were centrifuged and 
the radioactivity of  both pellet and supernatant determined. Cell damage 
is expressed as percent of total radioactivity released from the cells into 
the supernatant. 
TABLE  V 
Reduction  of C l q Hemolytic Activity by C l qR 
Percent he-  Percent 
Reaction mixture  molysis  inhibition 
(Clq + GVB) + ClqD + EA*  89  -- 
(Clq + CIqR) + ClqD + EA  40  55* 
* Highly purified Clq was incubated either with GVB or 5 #g/ml ClqR 
before addition to Clq-depleted  serum (ClqD) in the presence of 20 
mM CaCI~. Hemolysis  was expressed as percent of NHS-induced hemo- 
globin release. 
* The effect of ClqR is limited in part by the concentration of detergent 
(NP-40). 
that  a  proteoglycan  constitutes  a  part  of the  complex.  However,  amino  acid 
analysis together with the glucosamine-to-galactosamine ratio and the insensitiv- 
ity of the C 1  q receptor to digestion with chondroitinase seem to distinguish the 
C 1  q  receptor from the serum C 1  q  inhibitor, which has been previously charac- 
terized as chondroitin 4-sulfate proteoglycan (31). It is likely, however, that the 
C 1  qR and serum C 1  q inhibitor represent functional counterparts, in as much as 
both  macromolecules are  able  to  inhibit  most  of the  Clq-dependent  biologic 
reactions (23). Upon electrophoresis on SDS gels, the C 1  qR was shown to consist 
of a  single  protein  band  of 80-90,000  mol  wt  which,  upon  reduction,  stains 
heavier, with a single band of ~60-70,000 mol wt. The ultracentrifugation data 
and the SDS-PAGE profile taken together suggest that the ClqR is a  polymeric 
structure consisting of a protein portion noncovalently linked to a proteoglycan. 
The biological significance of the receptor cannot be determined from these 
studies. It is clear, however, that the receptor does bind only to free C 1  q.  Upon 
activation  of  the  classical  pathway  of  complement  by immune__ complexes, 
cT-INA, the plasma  inhibitor of activated C1, binds to Clr and Cls to form an 
irreversible complex, and thus readily dissociates them from the C 1  q  molecule. 
Under  these  conditions,  the  collageneous  tail  of the  Clq  molecule  becomes 
exposed and  possibly available  to bind to cell surface receptors on monocytes, 
iymphocytes,  or  polymorphonuclear  cells  (PMN),  though  this  type  of Clq  is 
believed  to  be  conformationaily  changed  (38).  Whether  binding  of  a  Clq- GHEBREHIWET, SILVESTRI, AND McDEVITT  1387 
containing immune complex to a  phagocytic cell Clq receptor represents one 
mechanism of immune clearance remains to be investigated. The binding of free 
Clq  to  cells possessing receptors for Clq  promotes biological functions, as is 
apparent from studies which found that ~lCr-labeled, Clq-Ec could be lysed by 
Raji cells as well as by lymphoblastoid cells in  the absence of anti-target cell 
antibody (15). This C l q-mediated cellular cytotoxicity could be inhibited if the 
C lq-coated target cells were first pretreated with ClqR  (15).  In addition, Clq 
has been reported (18-20)  to  inhibit collagen-dependent platelet aggregation 
and serotonin release. Whether this inhibition is mediated by a specific platelet 
receptor for Clq or if the platelet recognizes the collagen portion of the Clq 
through a specific receptor for collagen is not clear. The C l q receptor isolated 
from Raji cells is similar if not identical to the receptor on PMN or platelets, as 
has  been  confirmed  through  immunoprecipitation  studies  using  C lq-coated 
Sepharose beads and murine monoclonal antibody raised to the receptor (man- 
uscript in preparation). More work is needed to determine the precise function 
of cellular C I q receptor. 
Summary 
We have shown previously that an activity which is capable of precipitating 
purified C l q and inhibiting some of the C1 q-dependent biologic reactions could 
be solubilized from the membranes of both normal human peripheral B lympho- 
cytes and a  B  cell-derived lymphoblastoid cell  line (Raji),  both  of which are 
known to possess receptors for human C l q.  In this report we present evidence 
that this membrane-associated Clq inhibitor is a chondroitinase-insensitive ma- 
cromolecule and is the receptor for human C lq. The receptor was solubilized 
from membranes of Raji cells with Nonidet P-40 and purified to homogeneity 
using C 1  q-Sepharose 4B affinity chromatography. Equilibrium density gradient 
centrifugation analysis revealed that the complex could be resolved into a protein- 
rich, low density fraction and a  carbohydrate-rich, high density fraction. The 
large hydrodynamic size, coupled with the high buoyant density, suggests that a 
proteoglycan is  a  constituent of the complex and  indicates  that  the receptor 
might be a  macromolecular complex of a  proteoglycan portion noncovalently 
linked to a 60-70 kD glycoprotein. The glycoprotein moiety, in turn, consists of 
two  or  more  identical  (70,000  mol  wt)  polypeptide  chains  held  together by 
disulfide bonds and constitutes the Clq receptor (ClqR). Sucrose density ultra- 
centrifugation  analysis  showed  that  the  isolated  receptor  sediments  with  an 
apparent rate of 4.2  S.  Immunochemical analyses demonstrated that a  typical 
preparation  of the  ClqR  complex consists  of -23%  uronic  acid  and  ~21% 
galactosamine with a galactosamine-to-glucosamine ratio of 3.2. Binding of C l q 
to the receptor was found to  be optimal at low ionic strength and neutral or 
near-neutral pH (7-7.4). The isolated receptor was found to inhibit Clq hemo- 
lytic function, abrogate C l q-dependent rosette formation, and block the C l q- 
dependent, cell-mediated cytotoxicity, all of which are activities mediated by the 
receptor. 
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